Evaluation of Dosimetric Parameters and Disease Response After 125Iodine Transperineal Brachytherapy for Low- and Intermediate-Risk Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 5, 2009, Pages 1432-1438

  Morris, W James ^a   Keyes, Mira ^a   Palma, David ^a   McKenzie, Michael ^a   Spadinger, Ingrid ^a   Agranovich, Alex ^b   Pickles, Tom ^a   Liu, Mitchell ^b   Kwan, Winkle ^b   Wu, Jonn ^a   Lapointe, Vince ^a   Berthelet, Eric ^c   Pai, Howard ^c   Harrison, Robert ^a   Kwa, William ^a   Bucci, Joe ^d   Racz, Violet ^a   Woods, Ryan ^e  

^a Vancouver Cancer Centre   (Canada)

^b Fraser Valley Cancer Centre   (Canada)

^c Vancouver Island Cancer Centre   (Canada)

^d ST GEORGE HOSPITAL   (Australia)

^e Population and Preventive Oncology   (Canada)

Author keywords

Androgen deprivation; Brachytherapy; Dosimetry; Prostate cancer

Indexed keywords

ABERRATIONS; COMPUTERIZED TOMOGRAPHY; DECISION MAKING; DOSIMETRY; IODINE; MAGNETOPLASMA; MULTIVARIANT ANALYSIS; PATIENT MONITORING;

ANDROGEN DEPRIVATION; ANDROGEN DEPRIVATION THERAPIES; BIOCHEMICAL FAILURES; BRACHYTHERAPY; BRITISH COLUMBIA; CT SCANS; DOSIMETRIC PARAMETERS; MULTI-VARIATE ANALYSIS; PERIPHERAL DOSE; POST IMPLANTATIONS; PROSTATE BRACHYTHERAPY; PROSTATE CANCER; UNIVARIATE;

DOSIMETERS;

ANTIANDROGEN; GONADORELIN AGONIST; IODINE 125;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DOSIMETRY; FOLLOW UP; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; EPIDEMIOLOGIC METHODS; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RECURRENCE; TUMOR BURDEN;

EID: 62649113380     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.07.042     Document Type: Article

References (22)

1. Cooperberg M.R., Lubeck D.P., Meng M.V., et al. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141-2149
2. Wallace K., Fleshner N., Jewett M., et al. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: The Toronto Experience With the Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol 24 (2006) 4158-4162
3. Morris W.J., Keyes M., Palma D., et al. A population based study of biochemical and survival outcomes following permanent 125 Iodine brachytherapy for low- and intermediate-risk prostate cancer. Urology (2008) In press
4. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys 64 (2006) 825-834
5. Macdonald A.G., Keyes M., Kruk A., et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys 63 (2005) 155-163
6. Bucci J., Morris W.J., Keyes M., et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 53 (2002) 91-98
7. Keyes M., Liu M., Hilts M., et al. Anterior rectal wall DVH after I-125 permanent prostate implant: Can we use it to predict rectal toxicity?. [abstract 17]. Radiother Oncol 76 Suppl. (2005) S5-S6
8. 125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy. Int J Radiat Oncol Biol Phys 60 (2004) 40-50
9. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
10. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
11. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
12. Ash D., Al-Qaisieh B., Bottomley D., et al. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer. Radiother Oncol 79 (2006) 185-189
13. Lukka H., Warde P., Pickles T., et al. Controversies in prostate cancer radiotherapy: Consensus development. Can J Urol 8 (2001) 1314-1322
14. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 12 (2002) 81-94
15. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
16. 125I monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys 70 (2008) 96-101
17. Lee W.R., Roach M., Michalski J., et al. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys 54 (2002) 457-461
18. 125I prostate brachytherapy dose evaluation. Med Phys 30 (2003) 1897-1908
19. Merrick G.S., Butler W.M., Galbreath R.W., et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 51 (2001) 41-48
20. Sidhu S., Morris W.J., Spadinger I., et al. Prostate brachytherapy postimplant dosimetry: A comparison of prostate quadrants. Int J Radiat Oncol Biol Phys 52 (2002) 544-552
21. D'Amico A.V., Davis A., Vargas S.O., et al. Defining the implant treatment volume for patients with low risk prostate cancer: Does the anterior base need to be treated?. Int J Radiat Oncol Biol Phys 43 (1999) 587-590
22. Merrick G.S., Gutman S., Andreini H., et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 52 (2007) 715-724